Skip to main content

Table 1 Clinical features of plasmablastic lymphoma patients in this study group

From: Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patients

 

Total

PBL-HIV

PBL-PT

PBL-AD

PBL-IC

p value

p value

p value

N (%)

N (%)

N (%)

N (%)

N (%)

(HIV vs. IC)

(HIV vs. other)

(IC vs. other)

Patientsa

61 (100)

20 (33)

3 (5)

4 (7)

23 (38)

   

Age

     

0.026

0.006

0.141

Median (years)

49.2

41.7

66

52

55.7

   

Range (years)

21–83

30–63

29.1–73.0

38–76

26–81

   

Sex

     

0.075

0.092

0.073

Male

49 (80)

19 (95)

2 (67)

3 (75)

18 (78)

   

Female

12 (20)

1 (5)

1 (33)

1 (25)

5 (22)

   

Race

     

0.362

0.275

0.203

Caucasian

33 (54)

11 (55)

3 (100)

1 (25)

12 (52)

   

Hispanic

9 (15)

2 (10)

 

1 (25)

5 (22)

   

Black

2 (3)

2 (10)

  

0

   

Asian

7 (12)

2 (10)

 

1 (25)

3 (13.0)

   

Unspecified

10 (16)

3 (15)

 

1 (25)

3 (13.0)

   

Site(s) of involvementb

     

0.469

0.526

0.406

Nasal/oral cavity

21/46 (46)

9 (45)

  

6 (26)

   

Lymph node

34/49 (69)

14 (70)

1/1 (100)

1/2 (50)

13/21 (62)

   

GI tract

12 (20)

3 (15)

1(33)

3 (75)

3 (13.0)

   

Bone

7 (12)

4 (20)

  

3 (13.0)

   

Bone marrow

8/44 (18)

1/18 (6)

1 (33)

1/3 (33)

4/18 (22)

   

Abdominal/pelvic cavity

6 (10)

2 (10)

1 (33)

1 (25)

2 (9)

   

Body fluid

6 (10)

1 (5)

1 (33)

 

2 (9)

   

Liver

2 (3)

1 (5)

 

1 (25)

    

Skin

2 (3)

       

Soft tissue

2 (3)

   

2 (9)

   

Retroperitoneum

2 (3)

1 (5)

1 (33)

     

Mediastinum

2 (3)

   

1 (4)

   

Tonsil

1 (2)

   

1 (4)

   

Testis

1 (2)

   

1 (4)

   

Penis

1 (2)

   

1 (4)

   

Spleen

1 (2)

1 (5)

      

Gynecologic organs

1 (2)

1 (5)

      

Breast

1 (2)

   

1 (4)

   

Bladder

1 (2)

   

1 (4)

   

Kidney

1 (2)

1 (5)

      

NA

1 (2)

   

0

   

Ann Arbor stage at diagnosis

    

0.979

0.577

0.619

I + II

19/43 (44)

4 (20)

 

1 (25)

6 (26)

   

III + IV

24/43 (56)

3 (15)

 

1 (25)

4 (17)

   

Chemotherapy

     

0.495

0.431

0.889

H-CVAD

16/42 (38)

5 (25)

1 (33)

2 (50)

8 (50)

   

CHOP

8/42 (19)

4 (20)

1 (33)

 

3 (13)

   

EPOCH

7/42 (17)

4 (20)

1 (33)

1 (25)

1 (4)

   

Other

11/42 (26)

1 (5)

 

1 (25)

6 (14)

   

Radiation therapy

18/41 (44)

5/15 (33)

1 (33)

0/3

11/18 (61)

   

Stem cell transplant

6/42 (14)

1/15 (7)

1 (33)

0/3

4/19 (21)

   

Survival (months)

     

0.198

0.500

0.184

Median

7

14

35

2

17

   

Range

0.3–156

0.3–120

9–156

1–7

0.2–150

   

Status at last follow-up

        

Dead

43 (71)

15 (75)

3 (100)

2 (50)

6 (26)

   

Alive

18 (30)

5 (25)

0

2 (50)

17 (74)

   
  1. PBL plasmablastic lymphoma, HIV human immunodeficiency virus, PT post-transplant, AD autoimmune disease, IC immunocompetent, EPOCH etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, CHOP cyclophosphamide, doxorubicin, vincristine, prednisone, H-CVAD hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, cytarabine, NA not available
  2. aHIV status for 11 patients was unknown
  3. bSome patients had more than one site of involvement; therefore, the cumulative data may exceed 100 %
Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us